Table 2.
Trouble falling asleep: 18549∼20245 obs from 3036∼3045 women OR (95% CI) | Wake up several times: 18544∼20239 obs from 3036∼3045 women OR (95% CI) | Wake up early: 18545∼20242 obs from 3036∼3045 women OR (95% CI) | |
---|---|---|---|
Menopausal Status | P < 0.0001 | P < 0.0001 | P < 0.0001 |
Premenopausal (no HT) | 1.00 | 1.00 | 1.00 |
Early perimenopausal (no HT) | 1.36 (1.11, 1.67)** | 1.41 (1.21, 1.63)*** | 1.20 (1.00, 1.44)* |
Late perimenopausal (no HT) | 1.95 (1.45, 2.63)*** | 2.39 (1.92, 2.97)*** | 1.93 (1.48, 2.50)*** |
Postmenopausal (no HT) | 2.35 (1.75, 3.17)*** | 2.24 (1.79, 2.80)*** | 1.54 (1.18, 2.01)** |
Surgically menopausal (no HT) | 3.34 (2.13, 5.23)*** | 2.52 (1.73, 3.67)*** | 2.05 (1.34, 3.12)** |
Unknown† | 1.87 (1.39, 2.52)*** | 1.52 (1.22, 1.90)*** | 1.58 (1.22, 2.06)** |
Postmenopausal (HT) | 1.24 (0.78, 1.97) | 1.44 (1.05, 1.98)* | 1.17 (0.79, 1.72) |
Surgically menopausal (HT) | 1.44 (0.81, 2.54) | 1.90 (1.23, 2.92)** | 1.93 (1.19, 3.13)** |
Vasomotor symptoms | P < 0.0001 | P < 0.0001 | P < 0.0001 |
None | 1.00 | 1.00 | 1.00 |
< 6 days/2 weeks | 1.86 (1.59, 2.18)*** | 1.68 (1.51, 1.87)*** | 1.70 (1.49, 1.94)*** |
6–14 days/2 weeks | 5.28 (4.44, 6.28)*** | 4.89 (4.29, 5.58)*** | 3.89 (3.34, 4.52)*** |
E2 (log scale) ‡ | |||
Baseline | 1.14 (0.97, 1.34) | 1.08 (0.95, 1.22) | 1.03 (0.89, 1.18) |
Change since baseline | 1.15 (1.07, 1.24)*** | 1.12 (1.07, 1.18)*** | 1.06 (0.99, 1.13) |
FSH (log scale) | |||
Baseline FSH | 1.02 (0.86, 1.22) | 1.08 (0.95, 1.22) | 1.04 (0.90, 1.21) |
Change since baseline | 1.10 (1.01, 1.21)* | 1.20 (1.12, 1.28)*** | 1.07 (0.99, 1.16) |
Abbreviations: OR, odds ratio; CI, confidence interval; FSH, follicle stimulating hormone; E2, estradiol; obs, observations (note: numbers of obs and women differ slightly across models due to small differences in missing information between dependent variables and independent variables and covariates).
Estimates were adjusted for time-varying age.
“Unknown” category of menopausal status indicates those women who used hormone therapy but were not postmenopausal yet.
Estimates presented for decreasing E2.
Note: *P < 0.05; **P < 0.01; ***P < 0.001.